Abstract
Background
Though cardiovascular (CV) risks are reported in first-degree relatives (FDR) of type 2 diabetics, the pathophysiological mechanisms contributing to these risks are not known. We investigated the association of sympathovagal imbalance (SVI) with CV risks in these subjects.
Subjects and Methods
Body mass index (BMI), basal heart rate (BHR), blood pressure (BP), rate-pressure product (RPP), spectral indices of heart rate variability (HRV), autonomic function tests, insulin resistance (HOMA-IR), lipid profile, inflammatory markers, oxidative stress (OS) marker, rennin, thyroid profile and serum electrolytes were measured and analyzed in subjects of study group (FDR of type 2 diabetics, n = 72) and control group (subjects with no family history of diabetes, n = 104).
Results
BMI, BP, BHR, HOMA-IR, lipid profile, inflammatory and OS markers, renin, LF-HF (ratio of low-frequency to high-frequency power of HRV, a sensitive marker of SVI) were significantly increased (p<0.0001) in study group compared to the control group. SVI in study group was due to concomitant sympathetic activation and vagal inhibition. There was significant correlation and independent contribution of markers of insulin resistance, dyslipidemia, inflammation and OS to LF-HF ratio. Multiple-regression analysis demonstrated an independent contribution of LF-HF ratio to prehypertension status (standardized beta 0.415, p<0.001) and bivariate logistic-regression showed significant prediction (OR 2.40, CI 1.128–5.326, p = 0.002) of LF-HF ratio of HRV to increased RPP, the marker of CV risk, in study group.
Conclusion
SVI in FDR of type 2 diabetics occurs due to sympathetic activation and vagal withdrawal. The SVI contributes to prehypertension status and CV risks caused by insulin resistance, dyslipidemia, inflammation and oxidative stress in FDR of type 2 diabetics.
Introduction
Recently it has been reported that Asian Indian phenotype is exceptionally predisposed to develop diabetes because of strong familial aggregation and abrupt change in lifestyle [1]. As reported by World Health Organization (WHO), the total number of diabetic population was 171 million in 2000, which is projected to rise up to 366 million in 2030 [2]. India has been declared as the diabetic capital of world [3], [4]. It has been observed recently that the cardiovascular disease (CVD) and diabetes in developing countries are quite prevalent in the younger age group that has serious economic implications [4]. Diabetes shares several risk factors with CVD and the risk for CVD escalates with the co-occurrence of diabetes [4]. Therefore, early detection and treatment of diabetes and CVD, especially in younger population is among the key health policies worldwide [5]. The screening for diabetes and CVD in high risk population is a major strategy to achieve this goal [6]. The first degree relatives (FDR) of diabetic patients have been identified to have higher risk of developing diabetes compared to the general population [7]. Also, reports have confirmed increased cardiovascular (CV) risks and prevalence of CVD in this high risk population [8], [9].
Recently, decreased heart rate variability (HRV) and sympathovagal imbalance (SVI) have been reported to be associated with CV morbidities and mortalities [10], [11]. SVI has been attributed as the primary pathophysiologic basis of metabolic dysregulation in diabetes mellitus [12], [13]. An earlier report indicates modified autonomic balance with sympathetic hyperactivity in FDR of diabetic patients [14]. However, one report suggests that HRV is preserved in FDR of diabetics if they do not have metabolic complications [15]. The metabolic complications reported in FDR of diabetic patients are low-grade inflammation, insulin resistance and hyperlipidemia [16]–[18]. All these metabolic abnormalities are known risk factors for CVD [19]. Though autonomic imbalance has been reported in FDR of diabetics [14], [15] and inflammation, insulin resistance & dyslipidemia have been reported to induce SVI [20]–[23], to best of our knowledge no study has been conducted to date to assess the contribution of SVI to CV risks in FDR of type 2 diabetic patients. Though oxidative stress (OS) has recently been implicated in the causation of insulin resistance and diabetes [24], no study has assessed OS in FDR of type 2 diabetics. Therefore, in the present study, we have assessed the contribution of OS and other metabolic derangements to the SVI and CV risks in this high risk population.
Recently, spectral analysis of HRV has been established as a sensitive tool for assessment of autonomic functions in health and diseases [25]. Therefore, in the present study we have assessed the association of SVI with the CV risks in FDR of diabetic patients by analysing the spectral indices of HRV, in addition to the evaluation of autonomic function by conventional autonomic function tests (CAFT).
Methods
This is a cross-sectional blinded study. Volunteers who participated in the study were not aware about which group they belonged to during the study, as the grouping was done after compiling the family history of diabetes. This study was conducted as part of hypertension research project. After obtaining the approval of Research Council and Institutional Ethics Committee, of Jawaharlal Institute of Post-graduate Medical Education and Research (JIPMER), Puducherry, India, 176 subjects were recruited from undergraduate and postgraduate courses of JIPMER of 2011–2012 batch. Written informed consent was obtained from all the participants prior to commencement of the study procedures. They were classified into two groups.
Control group (n = 104): Normal healthy subjects without family history of diabetes.
Study group (n = 72): Normal healthy first degree relatives (FDR) with family history of type 2 diabetes mellitus. Subject of study group (FDR with history of type 2 diabetics) was defined as the subject having either of the parents or siblings diagnosed to have type 2 diabetes mellitus for at least one year and receiving treatment for the same. This was done through questionnaires and interview.
Healthy subjects (subjects without illness) were included in the study. Subjects receiving any medication, subjects with history of diabetes, smoking, hypertension, and hypertensive patients receiving medication were excluded from the study.
Recording of Anthropometric and Basal CV Parameters
Subjects were asked to report to autonomic function testing (AFT) laboratory of Physiology Department at about 9 AM following a light breakfast, without tea or coffee. After obtaining the written informed consent, their age, height and body weight were recorded and body mass index (BMI) was calculated. The temperature of AFT laboratory was maintained at 25°C for all the recordings. As per the procedure of blood pressure (BP) recording recommended by joint national committee (JNC-7) on classification of BP [26], after twenty minutes rest in upright sitting position on an armed chair, systolic blood pressure (SBP), diastolic blood pressure (DBP) and basal heart rate (BHR) were recorded using Omron (SEM 1 Model) automatic BP monitor (Omron Healthcare Co. Ltd, Kyoto, Japan), and mean arterial pressure (MAP) was calculated. Rate pressure product (RPP) was calculated using the formula, RPP = systolic pressure×heart rate×10−2 [27].
The category of ‘prehypertension’ or ‘normotension’ was decided based on the level of BP of the subjects. When SBP was >120 mm Hg or DBP was >80 mmHg or both, the subject was considered as prehypertensive, as per the JNC-7 classification of BP [26]. Prehypertension status was calculated using the Statistical Package for the Social Sciences (SPSS). For the purpose, depending on the BP level, the 0 and 1 values were assigned to normotensives and prehypertensives respectively for consideration of the prehypertension status. Accordingly, the groups 0 and 1 were categorized for determination and analysis of prehypertension status in both control and study groups by the SPSS software.
Recording of HRV
After 15 minutes of supine rest on a couch in AFT lab, ECG was recorded for 10 minutes for short-term HRV analysis following the standard procedure as recommended by Task Force on HRV [28]. For the purpose, ECG electrodes were connected and Lead II ECG was acquired at a rate of 1000 samples/second during supine rest using BIOPAC MP 100 data acquisition system (BIOPAC Inc., Goleta, CA, USA). The data was transferred from BIOPAC to a windows-based PC with AcqKnowledge software version 3.8.2. Ectopics and artefacts were removed from the recorded ECG. HRV analysis was done using the HRV analysis software version 1.1 (Bio-signal Analysis group, Kuopio, Finland). Frequency domain indices such as total power (TP) of HRV, normalized low-frequency power (LFnu), normalized high-frequency power (HFnu), ratio of low-frequency to high-frequency power (LF-HF ratio) and time-domain indices such as mean heart rate (Mean RR), square root of the mean squared differences of successive normal to normal intervals (RMSSD), Standard deviation of normal to normal interval (SDNN), the number of interval differences of successive NN intervals greater than 50 ms (NN50) and the proportion derived by dividing NN50 by the total number of NN intervals (pNN50) were calculated.
Conventional Autonomic Functions Tests (CAFTs)
Three CAFTs were performed following the standard procedures [29].
Lying to standing test (HR and BP response to standing)
The BP and ECG were recorded in supine position. The subject was instructed to attain standing posture in 3 seconds. The ECG was continuously recorded during the procedure. The BP was recorded every 40 seconds by automatic BP monitor (Omron, SEM-1, Kyoto, Japan) till 5th min. The 30∶15 ratio (ratio of maximum RR interval at 30th beat to minimum RR interval at 15th beat following standing) was calculated.
Deep breathing test (HR response to deep breathing)
The subject in sitting posture, HR and respiration monitoring was done from ECG recording and stethographic respiratory tracings recorded on the multichannel polygraph (Nihon-Kohden, Kyoto, Japan). A baseline recording of ECG and respiration was taken for 30 seconds. The subject was asked to take slow and deep inspiration followed by slow and deep expiration such that each breathing cycle lasted for 10 seconds, consisting of six breathing cycles per minute. The E∶I ratio (ratio of average RR interval during expiration to average RR interval during inspiration in six cycles of deep breathing) was calculated from ECG tracing.
Isometric handgrip test (BP response to isometric handgrip)
The baseline BP was recorded. The subject was asked to press handgrip dynamometer at 30% of maximum voluntary contraction for 2 minutes. The BP was recorded at 1st minute and 2nd minute of contraction. ΔDBPIHG (maximum rise in diastolic BP above baseline) was noted.
Measurement of Biochemical Parameters
Five ml of fasting blood sample was collected. The serum was separated from the blood samples of all the subjects for estimation of biochemical parameters. Free tri-iodothyronine (fT3), free thyroxine (fT4), thyroid stimulating hormone (TSH) and insulin were assayed by chemiluminiscence method using the kits of Siemens Healthcare Diagnostics Inc. (Tarrytown, NY, USA). Fasting blood glucose (FBG) was estimated by glucose oxidase method using glucometer (LifeScan Inc, Milpitas, CA, USA). For determination of insulin resistance, homeostatic model assessment of insulin resistance (HOMA-IR) was calculated by using the formula, HOMA-IR = FBS(mMol)×Insulin(μIU/L)/22.5.
Lipid profile (total cholesterol, triglycerides, high-, low- and very low-density lipoproteins) and serum electrolytes (Na+, Cl−, K+ and Ca++) were assessed using fully automated chemistry analyzer (AU400, Olympus, Orlando, FL, USA). Atherogenic index (AI) was calculated using the formula, log10(TG/HDL). The high-sensitive C-reactive protein (hsCRP) was estimated by enzyme immunoassay method using ELISA kit (dbc Diagnostics Biochem Canada Inc, Ontario, Canada). Interleukin-6 (IL6) was measured by enzyme immunoassay method using ELISA kit (Ani Biotech Oy, Tiilitie, Finland). Tumor necrosis factor-α (TNFα) was estimated by enzyme immunoassay method using ELISA kit (Ani Biotech Oy, Tiilitie, Finland). Oxidative stress was assessed by estimating thiobarbituric acid reactive substance (TBARS) using ELISA kit (Cayman Chemical Co., Ann Arbor, MI, USA). Renin was estimated by enzyme immunoassay method using the ELISA kit of DRG Diagnostics (DRG Instruments GmbH, Frauenbergstr, Marburg, Germany).
Statistical Analysis of Data
SPSS version 13 (SPSS Software Inc., Chicago, IL, USA) and GraphPad InStat softwares (GraphPad Software Inc., San Diego, CA, USA) were used for statistical analysis. All the data were presented as mean±SD. Normality of data was tested by Kolmogorov Smironov test. For parametric data, the level of significance between the groups was tested by Student's unpaired ‘t’ test and for nonparametric data, the Welch's corrected t test was used. The association between LF-HF ratio with BMI, BHR, blood pressure parameters, HOMA-IR, lipid parameters, inflammatory markers and TBARS was assessed by Pearson's correlation analysis. The independent contribution of various parameters to LF-HF ratio was assessed by multiple regression analysis. The parameters that had significant association with LF-HF ratio in Pearson's correlation were considered for multiple regression. Multiple regression analysis was applied to evaluate the effects of independent variables such as BMI, markers of insulin resistance, inflammation, oxidative stress and prehypertension status on LF-HF ratio, the dependant variable. The prediction of LF-HF of HRV to increased RPP was assessed by bivariate logistic regression. As higher level of RPP has been documented as an established CV risk, and LF-HF ratio of HRV as the primary marker of SVI, LF-HF ratio was considered as the independent variable to assess impact of SVI on CV risk due to increased RPP, the dependent variable in the logistic regression analysis. The p value less than 0.05 was considered statistically significant.
Results
Age, BMI and CV Parameters
There was no significant difference in age (p = 0.4419) between the subjects of control group and study group (Table 1). The BMI, BHR, SBP, DBP, MAP and RPP of study group subjects were significantly more (p<0.0001) compared to that of control group subjects (Table 1).
Table 1. Comparison of age, body mass index (BMI), cardiovascular (CV) parameters, frequency domain indices (FDI) and time domain indices (TDI) of heart rate variability (HRV) and conventional autonomic function testing (CAFT) parameters of control group (subjects with no family history of diabetes) and study group (first degree relatives of type 2 diabetics) subjects.
| Parameters | Control Group (n = 104) | Study group (n = 72) | P-Value |
| Age (years) | 20.95±2.56 | 21.28±3.10 | 0.4419 |
| BMI (kg/m2) | 23.30±3.64 | 26.95±3.50 | <0.0001 |
| Cardiovascular Parameters | |||
| BHR (per min) | 70.80±8.68 | 81.35±9.76 | <0.0001 |
| SBP (mmHg) | 110.20±6.86 | 119.84±7.32 | <0.0001 |
| DBP (mmHg) | 69.70±5.78 | 78.30±6.60 | <0.0001 |
| MAP (mmHg) | 83.30±6.55 | 92.24±6.40 | <0.0001 |
| RPP(mmHg/min) | 78.10±7.36 | 97.50±8.20 | <0.0001 |
| FDI of HRV | |||
| TP (ms2) | 940.60±245.26 | 656.40±194.75 | <0.0001 |
| LFnu | 40.12±15.52 | 58.40±18.16 | <0.0001 |
| HFnu | 59.24±17.34 | 42.12±14.60 | <0.0001 |
| LF∶HF ratio | 0.67±0.31 | 1.41±0.68 | <0.0001 |
| TDI of HRV: | |||
| Mean RR (s) | 0.847±0.12 | 0.737±0.11 | <0.0001 |
| RMSSD (ms) | 60.30±20.70 | 38.35±14.60 | <0.0001 |
| SDNN (ms) | 45.26±18.25 | 30.42±11.42 | <0.0001 |
| NN50 | 50.78±18.65 | 28.40±10.20 | <0.0001 |
| pNN50 | 30.67±13.10 | 20.60±8.90 | <0.0001 |
| CAFT parameters | |||
| E∶I ratio | 1.45±0.28 | 1.25±0.25 | <0.0001 |
| 30∶15 ratio | 1.27±0.23 | 1.40±0.20 | <0.0001 |
| ΔDBPIHG | 20.18±5.35 | 26.82±6.20 | <0.0001 |
Data expressed as mean±SD. P value<0.05 was considered significant. BMI: Body mass index; BHR: Basal heart rate; SBP: Systolic blood pressure; DBP: Diastolic blood pressure; MAP: Mean arterial pressure; RPP: Rate-pressure product; TP: Total power; LFnu: Normalized low-frequency power; HFnu: Normalized high-frequency power; LF-HF ratio: Ratio of low-frequency to high- frequency power; Mean RR: Mean heart rate; RMSSD: The square root of the mean of the sum of the squares of the differences between adjacent NN intervals; SDNN: Standard deviation of normal to normal interval; NN50: The number of interval differences of successive NN intervals greater than 50; pNN50: The proportion derived by dividing NN50 by the total number of NN intervals; E∶I ratio: The ratio of average RR interval during expiration to that of during inspiration in six cycles of deep breathing; 30∶15 ratio: The ratio of maximum RR interval at 30th beat to minimum RR interval at 15th beat following standing; ΔDBPIHG: The maximum rise in DBP above baseline following 30% of maximum voluntary contraction by isometric handgrip method.
HRV and CAFT Parameters
Among the frequency domain indices of HRV, TP, and HFnu were significantly reduced (p<0.0001) and LFnu and LF-HF ratio were significantly increased (p<0.0001) in study group subjects compared to the control group subjects. All the time domain indices (mean RR, RMSSD, SDNN, NN50, pNN50) were significantly less (p<0.0001) in study group subjects compared to that of control group subjects. The E∶I ratio was significantly decreased, and ΔDBPIHG and 30∶15 ratio were significantly increased (p<0.0001) in study group subjects (Table 1).
Metabolic Biomarkers
FBG, insulin and HOMA-IR were significantly increased (p<0.0001), all lipid parameters (except HDL, which was decreased) and lipid risk factors were significantly increased (p<0.0001) in study group compared to the control group (Table 2). Inflammatory markers (IL6, hsCRP, TNFα), renin and TBARS were significantly increased (p<0.0001) in study group compared to the control group. There was no significant difference in thyroid profile parameters between the groups. Serum Na+, Cl−, Ca++ levels were increased and K+ level was decreased (p<0.0001) in study group compared to the control group (Table 2).
Table 2. Comparison of metabolic biomarkers between of control group (subjects with no family history of diabetes) and study group (first degree relatives of type 2 diabetics) subjects.
| Parameters | Control Group (n = 104) | Study group (n = 72) | P-Value |
| Insulin related parameters: | |||
| FBG (mg/dL) | 72.35±8.60 | 98.42±10.50 | <0.0001 |
| Insulin (μIU/mL) | 5.24±2.40 | 18.74±5.58 | <0.0001 |
| HOMA-IR | 1.30±0.75 | 4.56±1.60 | <0.0001 |
| Lipid related parameters | |||
| TC (mg/dL) | 150.10±25.60 | 186.70±27.54 | <0.0001 |
| TG (mg/dL) | 90.28±22.41 | 142.68±30.20 | <0.0001 |
| LDL (mg/dL) | 96.50±20.80 | 130.37±26.60 | <0.0001 |
| VLDL (mg/dL) | 18.15±5.12 | 28.60±7.20 | <0.0001 |
| HDL (mg/dL) | 45.20±8.70 | 35.46±6.90 | <0.0001 |
| TC/HDL | 3.30±1.20 | 5.28±1.50 | <0.0001 |
| TG/HDL | 2.02±0.86 | 4.10±1.20 | <0.0001 |
| LDL/HDL | 2.15±0.92 | 3.70±1.08 | <0.0001 |
| Atherogenic index (AI) | 0.35±0.13 | 0.59±0.15 | <0.0001 |
| Inflammatory markers | |||
| IL6 (pg/mL) | 30.22±10.56 | 92.45±25.20 | <0.0001 |
| hsCRP (ng/dL) | 540.40±120.30 | 986.80±150.20 | <0.0001 |
| TNFα (pg/mL) | 75.20±24.76 | 294.36±50.80 | <0.0001 |
| Oxidative stress marker: | |||
| TBARS (µM/L) | 2.05±0.60 | 4.14±1.10 | <0.0001 |
| Sympathetic marker: | |||
| Renin (pg/mL) | 35.36±13.46 | 72.80±15.50 | <0.0001 |
| Thyroid profile | |||
| fT3 (pg/mL) | 3.50±1.96 | 4.05±2.10 | 0.077 |
| fT4 (ng/dL) | 2.58±1.55 | 3.10±1.96 | 0.051 |
| TSH (μIU/mL) | 2.86±2.10 | 2.44±1.85 | 0.163 |
| Serum Electrolytes | |||
| Na+ (mEq/L) | 137.10±6.28 | 145.30±7.50 | <0.0001 |
| K+ (mEq/L) | 4.15±0.58 | 3.50±0.42 | <0.0001 |
| Cl− (mEq/L) | 97.30±7.54 | 108.87±10.70 | <0.0001 |
| Ca++ (mEq/L) | 9.24±0.74 | 9.92±1.10 | <0.0001 |
Data expressed as mean±SD. AI = Log10(TG/HDL); HOMA-IR = FBG(mMol)×Insulin(μIU/L)/22.5; FBG: Fasting blood glucose; HOMA-IR: homeostatic model assessment of insulin resistance; TC: Total serum cholesterol; TG: Triglyceride; LDL: Low-density lipoprotein; VLDL: Very low-density lipoprotein; HDL: High-density lipoprotein; IL6: Interleukin 6; hsCRP: high-sensitive C reactive protein; TNFα: Tumor necrosis factor α; TBARS: Thiobarbituric acid reactive substance; fT3: free tri-iodothyronine, fT4: free thyroxine; TSH: thyroid stimulating hormone.
Correlation and Regression Analysis
Though there was no significant correlation of LF-HF ratio with any of the parameter in control group, the correlation of BMI, CV parameters and metabolic factors with LF-HF ratio was significant in the study group (Table 3).
Table 3.Correlation. Correlation of LF-HF with various parameters in both the groups.
| Parameters | Control Group (n = 104) | Study group (n = 72) | ||
| r | p | r | p | |
| BMI | 0.086 | 0.182 | 0.254 | 0.038 |
| BHR | 0.097 | 0.155 | 0.365 | 0.004 |
| SBP | 0.110 | 0.120 | 0.325 | 0.012 |
| DBP | 0.102 | 0.132 | 0.270 | 0.024 |
| MAP | 0.128 | 0.092 | 0.340 | 0.008 |
| RPP | 0.072 | 0.186 | 0.342 | 0.008 |
| HOMA-IR | 0.156 | 0.068 | 0.710 | <0.001 |
| TC/HDL | 0.092 | 0.106 | 0.530 | <0.001 |
| TG/HDL | 0.072 | 0.186 | 0.538 | <0.001 |
| LDL/HDL | 0.065 | 0.210 | 0.435 | 0.001 |
| Atherogenic index | 0.150 | 0.060 | 0.576 | <0.001 |
| IL6 | 0.076 | 0.180 | 0.659 | <0.001 |
| hsCRP | 0.041 | 0.286 | 0.662 | <0.001 |
| TNFα | 0.130 | 0.080 | 0.682 | <0.001 |
| Renin | 0.115 | 0.109 | 0.350 | 0.007 |
| TBARS | 0.032 | 0.310 | 0.272 | 0.025 |
The p value <0.05 was considered significant. BMI: Body mass index; BHR: Basal heart rate; SBP: Systolic blood pressure; DBP: Diastolic blood pressure; MAP: Mean arterial pressure; RPP: Rate-pressure product; HOMA-IR: homeostatic model assessment of insulin resistance; TC: Total serum cholesterol; TG: Triglyceride; LDL: Low-density lipoprotein; HDL: High-density lipoprotein; IL6: Interleukin 6; hsCRP: high-sensitive C reactive protein; TNFα: Tumor necrosis factor α; TBARS: Thiobarbituric acid reactive substance.
Multiple regression analysis revealed significant individual contribution of HOMA-IR, AI, IL6, hsCRP, TNFα, TBARS and hypertension status, but not BMI to the LF-HF ratio in the study group (Table 4). Bivariate logisitic regression (Table 5) showed significant prediction of LF-HF ratio of HRV to RPP in study group (OR 2.40, CI 1.128–5.326; p = 0.002) compared to that of control group (OR 0.62, CI 0.446–2.352, p = 1.085).
Table 4. Multiple regression analysis of LF-HF (as dependent variable) with various parameters (as independent variables) in study group subjects.
| Independent Variables | Standardized Regression | 95% C.I. | p values | |
| Lower bound | Upper bound | |||
| BMI | 0.102 | −0.394 | 0.510 | 0.086 |
| HOMA –IR | 0.256 | 0.027 | 0.178 | 0.002 |
| AI | 0.132 | 0.001 | 0.042 | 0.038 |
| IL6 | 0.156 | 0.002 | 0.032 | 0.016 |
| hsCRP | 0.134 | 0.000 | 0.001 | 0.030 |
| TNFα | 0.356 | 0.002 | 0.005 | <0.001 |
| TBARS | 0.168 | −0.044 | 0.158 | 0.011 |
| PHTN status | 0.415 | 0.003 | 0.008 | <0.001 |
P values<0.05 considered significant. BMI: Body mass index; HOMA-IR: homeostatic model assessment of insulin resistance; AI: Atherogenic index; IL6: Interleukin 6; hsCRP: high-sensitive C reactive protein; TNFα: Tumor necrosis factorα; TBARS: Thiobarbituric acid reactive substance; PHTN status: Prehypertension status.
Table 5. Bivariate logistic regression analysis of RPP (as dependent variable) with LF-HF ratio of heart rate variability (as independent variable) in control group and study group subjects after adjusting for BMI.
| Control group | Study group | |||
| OR (95% C.I.) | p value | OR (95% C.I.) | p value | |
| LF-HF ratio | 0.62 (0.446 to 2.352) | 1.085 | 2.40 (1.128 to 5.326) | 0.002 |
p<0.05 considered significant; OR : odds ratio; RPP: rate pressure product; LF-HF: Ratio of low-frequency to high-frequency power of heart rate variability; C.I. : confidence interval.
Discussion
HRV and CAFT Parameters
In the study group, LF-HF ratio was significantly increased (p = 0.000) compared to the control group (Table 1) indicating a considerable enhancement in sympathetic activity in FDR of type 2 diabetics as increase in LF-HF ratio represents accentuation of sympathetic activity and decrease in this ratio represents facilitation of parasympathetic activity [25], [28]. As there was decrease in HFnu in FDR of type 2 diabetics, SVI in these subjects is due to decreased parasympathetic activity as decrease in HFnu represents decreased vagal modulation of cardiac drive [25], [28]. SVI in study group subjects could also be due to increase in sympathetic activity as there was increased LFnu, which reflects both sympathetic and parasympathetic drives to the heart [25], [28]. These findings corroborate with the reports of earlier studies [14], [15]. In addition, increase in ΔDBPIHG in study group subjects indicates increased sympathetic reactivity in FDR of type 2 diabetics [29].
The TP of HRV was significantly decreased in study group subjects (Table 1) representing a substantial decrease in HRV in FDR of type 2 diabetics as TP represents the quantum of HRV spectrum [25], [28]. The TP not only represents the magnitude of HRV, but also the overall vagal drive of cardiac modulation [25], [28]. Therefore, decreased TP of HRV has recently been observed to be associated with sudden cardiac death and cardiac morbidities [10], [11], [30], [31]. Thus, decreased TP in FDR of diabetics could predispose them to adverse CV events. This was further supported by significantly high BHR in these subjects (Table 1). Resting heart rate is an index of vagal tone [29], and increased BHR has recently been reported to be associated with increased CV risks [32]. The time-domain indices of HRV were significantly reduced in study group (Table 1) that further confirms decreased vagal tone in FDR of diabetics, as time-domain indices represent parasympathetic modulation of cardiac activity [25], [28]. Further, increased 30∶15 ratio and decreased E∶I ratio in these subjects (Table 1) reflect decreased vagal reactivity in FDR of type 2 diabetics [29].
Contribution of Metabolic Biomarkers to SVI
Though the exact cause of SVI can not be ascertained from the present study, insulin resistance could be a plausible mechanism as fasting blood glucose, plasma insulin and HOMA-IR were significantly high in study group (Table 2). Further, HOMA-IR was significantly correlated with LF-HF ratio in study group subjects (Table 2) and had significant independent contribution to LF-HF in these subjects (Table 4). As insulin resistance has been reported to cause autonomic imbalance (23), insulin resistance could contribute to SVI in FDR of type 2 diabetics. Further, these subjects are more prone to develop diabetes mellitus.
Low-grade inflammation has been reported in FDR of type 2 diabetics [16], and inflammatory markers such as hsCRP, IL6 and TNFα have been reported to induce SVI in various stress related disorders [20]. In the present study, not only IL6, hsCRP and TNFα were significantly high in study group (Table 2), but also they were significantly correlated with LF-HF ratio (Table 3). Moreover, each inflammatory marker had independent contribution to LF-HF ratio (Table 4), and TNFα had the highest influence. Thus, it appears that retrograde inflammation has strong contribution to SVI in FDR of type 2 diabetics, in which TNFα plays a pivotal role.
There are reports of dyslipidemia in FDR of type 2 diabetics [17], [18]. In the present study, all lipid profile parameters (except HDL) and lipid risk factors were significantly high in study group (Table 2) and lipid risk factors were significantly correlated with LF-HF ratio (Table 3). Moreover, in multiple regression model, AI had significant contribution to LF-HF ratio in study group subjects (Table 4), indicating that atherogenic lipid risk factors contribute to SVI in them. From among the lipid risk factors assessed in the present study, we selected AI for the regression model, as AI has recently been reported to be the better indicator of CV risk [33]. Increased plasma level of TG is reported to produce OS [34], and OS is known to induce SVI [35]. In the present study, TBARS was significantly more in study group (Table 2) and had significant correlation with LF-HF (Table 3). Moreover, TBARS had independent contribution to LF-HF in these subjects (Table 4). Thus, OS could be the link between the dyslipidemia and SVI in FDR of type 2 diabetics.
Influence of BMI
Obesity has been reported to be more prevalent in individuals with family history of diabetes [15]. In the present study, BMI was significantly high in study group (Table 1), and had significant correlation with LF-HF ratio (Table 3). However, in multiple regression analysis, BMI had no independent contribution to LF-HF ratio. Thus, increased BMI in FDR of type 2 diabetics is unlikely to be a potential contributor to SVI in these subjects. Salamin et al have recently reported that although BMI and subcutaneous adiposity are not associated with cardiac parasympathetic indices of HRV, visceral adiposity contributes to decreased HRV [36]. Therefore, future research warrants estimation of visceral fat and its correlation with SVI to assess the contribution of visceral adiposity to CV risks in FDR of type 2 diabetics.
RPP as CV risk
RPP is a measure of myocardial work load and oxygen consumption and increased RPP has been documented a CV risk [27]. In the present study, RPP was not only significantly increased in study group compared to the control group (Table 1), but also was significantly correlated with LF-HF ratio of HRV (Table 3). Therefore, it is expected that SVI in FDR of type 2 diabetics is linked to the myocardial stress, which could be an impending CV risk. As obesity per se is a CV risk factor, we assessed the independent association of RPP with LF-HF ratio by logistic regression adjusted for BMI (Table 5) and we found that LF-HF ratio significantly predicts RPP (OR, 2.40; CI, 1.128 to 5.326; p = 0.002) in these subjects. Thus, it appears that SVI in FDR of type 2 diabetics contributes to CV risks independent of BMI. Further, LF-HF ratio had independent contribution to prehypertension status as shown by multiple regression (Table 4), further indicating the increased CV risk in these subjects.
Link of SVI to CV risks
Prediabetes, prehypertension and insulin resistance in adolescents and young adults remain for a longer duration exposing them to premature CV risks before clinically manifesting as full blown diabetes and hypertension during their adulthood [37]. In the present study, in young FDR of type 2 diabetics, insulin resistance, atherogenic lipid profile, low-grade inflammation and oxidative stress were found to contribute to SVI. Findings of the present study indicate that SVI is the major link between the metabolic derangements and CV risks and chronic SVI could be the physiological basis for future CV morbidities in FDR of type 2 diabetics. However, further research warrants the evaluation of the impact of SVI achieved by various non-pharmacological means on reduction of prehypertension status and CV risks in these high risk young individuals, as practice of yoga and slow breathing exercises have been reported to decrease sympathetic discharge, increase vagal tone and improve metabolic functions [38], [39].
In summary, the results of the present study indicate the presence of SVI in the form increased sympathetic and decreased parasympathetic activity and reactivity in young FDR of type 2 diabetics. Resting tachycardia, decreased HRV, increased RPP, increased prehypertension status, insulin resistance, atherogenic lipid profile, low-grade inflammation and oxidative stress in these subjects make them vulnerable to augmented CV risks and SVI is the physiological basis for development of these CV risks. The present study suggests for future research to assess if restoration of sympathovagal homeostasis in FDR of type 2 diabetics can reduce the CV risks in these subjects.
Limitations of the Study
In the present study, though we have assessed the CV risks, we have not assessed CV functions by continuous BP variability analysis to determine CV reactivity and dysfunction. We have also not estimated plasma norepinephrine or its metabolites in urine to support SVI. We have not performed analysis of body fat composition to assess the influence of visceral fat on SVI in FDR of type 2 diabetics.
Funding Statement
These authors have no support or funding to report.
References
- 1. Joshi SR (2012) Type 2 diabetes in Asian Indians. Clin Lab Med 32: 207–216. [DOI] [PubMed] [Google Scholar]
- 2.International Diabetes Federation (2009) Diabetes Atlas. Brussels: International Diabetes Federation Publication. pp. 1–27. [Google Scholar]
- 3. Ginter E, Simko V (2012) Global prevalence and future of diabetes mellitus. Adv Exp Med Biol 771: 35–41. [DOI] [PubMed] [Google Scholar]
- 4. Pradeepa R, Prabhakaran D, Mohan V (2012) Emerging economies and diabetes and cardiovascular disease. Diabetes Technol Ther 14: 59–67. [DOI] [PubMed] [Google Scholar]
- 5. Laslett LJ, Alagona P Jr, Clark BA 3rd, Drozda JP Jr, Saldivar F, et al. (2012) The worldwide environment of cardiovascular disease: prevalence, diagnosis, therapy, and policy issues: a report from the American College of Cardiology. J Am Coll Cardiol 60: 1–49. [DOI] [PubMed] [Google Scholar]
- 6. Anselmino M, Rydén L (2009) Strategies to enhance cardiovascular disease prevention in patients with diabetes. Curr Opin Cardiol 24: 461–467. [DOI] [PubMed] [Google Scholar]
- 7. Karaman A, Bayram F, Gundogan K, Ozsan M, Karaman H, et al. (2012) Prevalence of diabetes mellitus and glucose metabolism disorders in the first degree relatives of type 2 diabetic patients. Bratisl Lek Listy 113: 361–367. [DOI] [PubMed] [Google Scholar]
- 8. Johansen NB, Hansen AL, Jensen TM, Philipsen A, Rasmussen SS, et al. (2012) Protocol for ADDITION-PRO: a longitudinal cohort study of the cardiovascular experience of individuals at high risk for diabetes recruited from Danish primary care. BMC Public Health 12: 1078 doi:10.1186/1471-2458-12-1078 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 9. Amini M, Horri N, Zare M, Haghighi S, Hosseini SM, et al. (2010) People with impaired glucose tolerance and impaired fasting glucose are similarly susceptible to cardiovascular disease: a study in first-degree relatives of type 2 diabetic patients. Ann Nutr Metab 56: 267–272. [DOI] [PubMed] [Google Scholar]
- 10. Thayer JF, Yamamoto SS, Brosschot JF (2010) The relationship of autonomic imbalance, heart rate variability and cardiovascular disease risk factors. Int J Cardiol 141: 122–131. [DOI] [PubMed] [Google Scholar]
- 11. Pal GK, Pal P, Nanda N, Amudharaj D, Adithan C (2013) Cardiovascular dysfunctions and sympathovagal imbalance in hypertension and prehypertension: physiological perspectives. Future Cardiol 9: 53–69. [DOI] [PubMed] [Google Scholar]
- 12. Fleischer J (2012) Diabetic autonomic imbalance and glycemic variability. J Diabetes Sci Technol 6: 1207–1215. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 13. Lieb DC, Parson HK, Mamikunian G, Vinik AI (2012) Cardiac autonomic imbalance in newly diagnosed and established diabetes is associated with markers of adipose tissue inflammation. Exp Diabetes Res 2012: 878760 doi:10.1155/2012/878760 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 14. Fiorentini A, Perciaccante A, Paris A, Serra P, Tubani L (2005) Circadian rhythm of autonomic activity in non diabetic offsprings of type 2 diabetic patients. Cardiovasc Diabetol 4: 15 doi:10.1186/1475-2840-4-15 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 15. Neves FJ, Bousquet-Santos K, Silva BM, Soares PP, Nóbrega AC (2008) Preserved heart rate variability in first-degree relatives of subjects with Type 2 diabetes mellitus without metabolic disorders. Diabet Med 25: 355–359. [DOI] [PubMed] [Google Scholar]
- 16. Ruotsalainen E, Vauhkonen I, Salmenniemi U, Pihlajamäki J, Punnonen K, et al. (2008) Markers of endothelial dysfunction and low-grade inflammation are associated in the offspring of type 2 diabetic subjects. Atherosclerosis 197: 271–277. [DOI] [PubMed] [Google Scholar]
- 17. Altinli S, Elevli M, Ozkul AA, Kara PG, Karsidag K, et al. (2007) Insulin resistance and metabolic syndrome in children of parents with diabetes mellitus. J Pediatr Endocrinol Metab 20: 431–436. [DOI] [PubMed] [Google Scholar]
- 18. Jirkovská A, Válek V, Skibová J, Poledne R, Petrásek R (1991) Arteriosclerosis risk factors in the offspring and siblings of type 2 diabetics. Vnitr Lek 37: 671–677. [PubMed] [Google Scholar]
- 19. Graham IM (2006) The importance of total cardiovascular risk assessment in clinical practice. Eur J Gen Pract 12: 148–155. [DOI] [PubMed] [Google Scholar]
- 20. Vinik AI (2012) The conductor of the autonomic orchestra. Front Endocrinol 3: 71 Epub 2012 Jun 21. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 21. Lambert E, Straznicky N, Sari CI, Eikelis N, Hering D, et al. (2013) Dyslipidemia is associated with sympathetic nervous activation and impaired endothelial function in young females. Am J Hypertens 26: 250–256. [DOI] [PubMed] [Google Scholar]
- 22. Lehnen AM, Leguisamo NM, Casali KR, Schaan BD (2013) Progressive cardiovascular autonomic dysfunction in rats with evolving metabolic syndrome. Auton Neurosci 2013 doi:pii: S1566-0702(13)00043-X. 10.1016/j.autneu.2013.02.011 [DOI] [PubMed] [Google Scholar]
- 23. Lindmark S, Lönn L, Wiklund U, Tufvesson M, Olsson T, et al. (2005) Dysregulation of the autonomic nervous system can be a link between visceral adiposity and insulin resistance. Obes Res 13: 717–728. [DOI] [PubMed] [Google Scholar]
- 24. Ruskovska T, Bernlohr DA (2013) Oxidative stress and protein carbonylation in adipose tissue - Implications for insulin resistance and diabetes mellitus. J Proteomics 2013 doi:[]10.1016/j.jprot. 2013.04.002. [Epub ahead of print] [DOI] [PMC free article] [PubMed] [Google Scholar]
- 25. Malliani A (2005) Heart rate variability: from bench to bedside. Europ J Int Med 16: 12–20. [DOI] [PubMed] [Google Scholar]
- 26.(2004) Classification of blood pressure. In: The seventh report of the joint national committee on prevention, detection, evaluation, and treatment of high blood pressure. National Heart, Lung and Blood Institute; National High Blood Pressure Education Program; NIH Publication, USA. [PubMed]
- 27. White WB (1999) Heart rate and the rate-pressure product as determinants of cardiovascular risk in patients with hypertension. Am J Hypertens 12: 50S–55S. [DOI] [PubMed] [Google Scholar]
- 28. Task force of the European Society of Cardiology and the North American society of Pacing and Electrophysiology (1996) Heart rate variability. Standard and measurement, physiological interpretation and clinical use. Circulation 93: 1043–1065. [PubMed] [Google Scholar]
- 29.Pal GK, Pal P (2010) Autonomic function tests. In: Textbook of Practical Physiology. Chennai: Universities Press. pp. 282–290. [Google Scholar]
- 30. Kiviniemi AM, Tulppo MP, Wichterle D, Hautala AJ, Tiinanen S, et al. (2007) Novel spectral indexes of heart rate variability as predictors of sudden and non-sudden cardiac death after an acute myocardial infarction. Ann Med 39: 54–62. [DOI] [PubMed] [Google Scholar]
- 31. Laitio T, Jalonen J, Kuusela T, Scheinin H (2007) The role of heart rate variability in risk stratification for adverse postoperative cardiac events. Anesth Analg 105: 1548–1560. [DOI] [PubMed] [Google Scholar]
- 32. Jensen MT, Suadicani P, Hein HO, Gyntelberg F (2013) Elevated resting heart rate, physical fitness and all-cause mortality: a 16-year follow-up in the Copenhagen Male Study. Heart 99: 882–887. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 33. Popa CD, Arts E, Fransen J, van Riel PL (2012) Atherogenic index and high-density lipoprotein cholesterol as cardiovascular risk determinants in rheumatoid arthritis: the impact of therapy with biologicals. Mediators Inflamm 2012: 785946 Epub 2012 Sep 6. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 34. Lupachyk S, Watcho P, Hasanova N, Julius U, Obrosova IG (2012) Triglyceride, nonesterified fatty acids, and prediabetic neuropathy: role for oxidative-nitrosative stress. Free Radic Biol Med 52: 1255–1263. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 35. Danson EJ, Paterson DJ (2006) Reactive oxygen species and autonomic regulation of cardiac excitability. Cardiovasc Electrophysiol 17: S104–S112. [DOI] [PubMed] [Google Scholar]
- 36. Salamin G, Pelletier C, Poirier P, Després JP, Bertrand O, et al. (2013) Impact of visceral obesity on cardiac parasympathetic activity in type 2 diabetics after coronary artery bypass graft surgery. Obesity (Silver Spring) 21: 1578–1585. [DOI] [PubMed] [Google Scholar]
- 37. May AL, Kuklina EV, Yoon PW (2012) Prevalence of cardiovascular disease risk factors among US adolescents, 1999–2008. Pediatrics 129: 1035–1041. [DOI] [PubMed] [Google Scholar]
- 38. Pal GK, Velkumary S, Madanmohan (2004) Effects of slow and fast breathing exercises on autonomic functions in young student volunteers. Ind J Med Res 3: 154–160. [PubMed] [Google Scholar]
- 39. Hegde SV, Adhikari P, Kotian S, Pinto VJ, D'Souza S, et al. (2011) Effect of 3- month yoga on oxidative stress in type 2 diabetes with or without complications: a controlled clinical trial. Diabetes Care 34: 2208–2210. [DOI] [PMC free article] [PubMed] [Google Scholar]